Skip to main content
SpringerLink
Log in

Assessment of cardiovascular risk and simultaneous treatment of multiple risk factors is important in patients with metabolic syndrome

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

References

  1. Sesti G, Volpe M, Cosentino F, et al. Metabolic syndrome: diagnosis and clinical management, an official document of the working group of the Italian Society of Cardiovascular Prevention (SIPREC). High Blood Press Cardiovasc Prev 2006; 13(4): 185–98

    Article  CAS  Google Scholar 

  2. Ferrucci A, Sciarretta S, Valenti V, et al. How to manage metabolic syndrome: clinical approach based on cardiovascular risk profile. High Blood Press Cardiovasc Prev 2005; 12(4): 231–38

    Article  Google Scholar 

  3. Wong ND. Metabolic syndrome: cardiovascular risk assessment and management. Am J Cardiovasc Drugs 2007; 7(4): 259–72

    Article  PubMed  CAS  Google Scholar 

  4. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735–52

    Article  PubMed  Google Scholar 

  5. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): 1245–50

    Article  PubMed  Google Scholar 

  6. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91(12): 1421–6

    Article  PubMed  Google Scholar 

  7. Third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): a final report. Circulation 2002; 106 (25): 3143-421

    Google Scholar 

  8. Stone NJ, Saxon D. Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. Am J Cardiol 2005; 96(4a): 15E–21E

    Article  PubMed  Google Scholar 

  9. Deedwania PS, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol 2004; 93(11A): 18c–26c

    Article  PubMed  CAS  Google Scholar 

  10. Volkova N, Deedwania PC. Dyslipidemia in the metabolic syndrome. In: Krentz AJ, Wong ND, editors. Metabolic syndrome and cardiovascular disease. New York: Informa Healthcare, 2007

  11. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and anti-hypertensive drugs. J Hypertens 2006; 24(1): 3–10

    Article  PubMed  CAS  Google Scholar 

  12. van Zwieten PA, Mancia G. Background and treatment of metabolic syndrome: a therapeutic challenge. Semin Cardiothorac Vasc Anesth 2006 Sep; 10(3): 206–14

    Article  PubMed  Google Scholar 

  13. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention and metformin. N Engl J Med 2002; 346(26): 393–403

    Google Scholar 

  14. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001; 344(18): 1343–50

    Article  CAS  Google Scholar 

  15. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368(9541): 1096–105

    Article  Google Scholar 

  16. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglatAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–89

    Article  PubMed  CAS  Google Scholar 

  17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–86

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Assessment of cardiovascular risk and simultaneous treatment of multiple risk factors is important in patients with metabolic syndrome. Drugs Ther. Perspect 24, 13–17 (2008). https://doi.org/10.2165/00042310-200824090-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824090-00004

Search

Navigation